15 May 2017 07:00
15 May 2017
AIM: REDX
Abstract #219
Poster #210
REDX PHARMA PLC
("Redx" or "the Company")
Preclinical data for reversible BTK inhibitor RXC005 presented at the 17th International Workshop of Chronic Lymphocytic Leukemia
Redx Pharma, the research and development company focused on cancer, immunology and infection, announces that preclinical efficacy data in mouse-models for its development candidate, RXC005, a reversible BTK inhibitor, has been presented in a poster session at the 17th International Workshop of Chronic Lymphocytic Leukemia (iwCLL) biennial meeting in New York City, U.S. on 14 May, 2017.
The poster, entitled "RXC005, a Potent and Selective, Reversible BTK Inhibitor Targeting both Wild-type and Mutant C481S BTK with Potent Efficacy in ABC-DLBCL Xenograft Mouse Models", demonstrated that RXC005 successfully inhibits wild-type BTK and C481S mutant BTK, as well as B-Cell Receptor signalling in ABC-DLBCL cell lines and importantly primary CLL cells.
RXC005 was also shown to be highly selective and exhibits improved target specificity against other Tec and Src kinase family members. RXC005 demonstrated significant efficacy in ABC-DLBCL xenograft mouse models such as TMD8 and OCI-Ly10 cell lines.
The poster can be found on the Company's website www.redxpharma.com
Dr Neil Murray, Chief Executive Officer of Redx Pharma, commented: "We are delighted to have presented further potent efficacy data for one of our lead development candidates, RXC005, at the prestigious iwCLL event in front of our peers and contemporaries."
Dr Richard Armer, Chief Scientific Officer of Redx Pharma, commented: "The data presented is further validation of RXC005's potential to target both wild-type and mutant BTK, an important emerging resistance mechanism in patients with CLL progression following ibrutinib treatment. With good target engagement demonstrated in the PK/PD studies and efficacy in mouse-models, we look forward to filing an IND/CTA in late 2017 to take RXC005 into the clinic."
For further information, please contact:
Redx Pharma Plc | |
Neil Murray, Chief Executive Officer | T: +44 1625 469 900 |
Karl Hård, Head of IR & Corporate Communications
| T: +44 7491 651 406 |
Cantor Fitzgerald Europe (Nomad & Broker) | T: +44 20 7894 7000 |
Phil Davies/ Michael Reynolds |
|
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Spång/ Chris Lee/ David Wilson |
|
Consilium Strategic Communications |
T: +44 20 3709 5700 |
Amber Fennell/ Matthew Neal/ Melissa Gardiner |
About Redx Pharma Plc
Company website: www.redxpharma.com
Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, immunology and infection providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.